Lomustine and Bevacizumab in Progressive Glioblastoma | Zendy

Wolfgang Wick | Zendy; Thierry Gorlia | Zendy; Martin Bendszus | Zendy; Martin Taphoorn | Zendy; Felix Sahm | Zendy; Inga Harting | Zendy; Alba A. Brandes | Zendy; Walter Taal | Zendy; Julien Dômont | Zendy; Ahmed Idbaïh | Zendy; Mario Campone | Zendy; Paul M. Clément | Zendy; Roger Stupp | Zendy; Michel Fabbro | Zendy; Émilie Le Rhun | Zendy; François Dubois | Zendy; Michael Weller | Zendy; Andreas von Deimling | Zendy; Vassilis Golfinopoulos | Zendy; Jacoline C. Bromberg | Zendy; Michael Platten | Zendy; Martin Klein | Zendy; Martin J. van den Bent | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lomustine and Bevacizumab in Progressive Glioblastoma

Author(s) -

Wolfgang Wick,

Thierry Gorlia,

Martin Bendszus,

Martin Taphoorn,

Felix Sahm,

Inga Harting,

Alba A. Brandes,

Walter Taal,

Julien Dômont,

Ahmed Idbaïh,

Mario Campone,

Paul M. Clément,

Roger Stupp,

Michel Fabbro,

Émilie Le Rhun,

François Dubois,

Michael Weller,

Andreas von Deimling,

Vassilis Golfinopoulos,

Jacoline C. Bromberg,

Michael Platten,

Martin Klein,

Martin J. van den Bent

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1707358

Subject(s) - lomustine , medicine , bevacizumab , hazard ratio , clinical endpoint , progression free survival , confidence interval , randomization , surgery , combination therapy , oncology , randomized controlled trial , chemotherapy , vincristine , cyclophosphamide

Bevacizumab is approved for the treatment of patients with progressive glioblastoma on the basis of uncontrolled data. Data from a phase 2 trial suggested that the addition of bevacizumab to lomustine might improve overall survival as compared with monotherapies. We sought to determine whether the combination would result in longer overall survival than lomustine alone among patients at first progression of glioblastoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research